What Is Bimzelx?
Bimzelx (bimekizumab-bkzx) is an injectable biologic drug approved by the FDA for treating moderate to severe plaque psoriasis in adults. It targets and blocks two cytokines—interleukin-17A (IL-17A) and interleukin-17F (IL-17F)—that drive inflammation in autoimmune skin conditions.[1]
How Does Bimzelx Work?
It binds directly to IL-17A and IL-17F, preventing them from activating immune pathways that cause psoriatic plaques. This dual blockade sets it apart from single-target IL-17 inhibitors like Cosentyx (secukinumab), potentially offering faster skin clearance for some patients.[1][2]
What Conditions Does Bimzelx Treat?
FDA approvals include:
- Plaque psoriasis (2023).
- Active psoriatic arthritis (2024).
- Moderate to severe hidradenitis suppurativa (2024).[1]
Ongoing trials explore non-radiographic axial spondyloarthritis and other inflammatory diseases.
How Is Bimzelx Administered and Dosed?
Patients self-inject 320 mg (two 160 mg/1.6 mL pre-filled syringes) subcutaneously every 4 weeks for the first 16 weeks, then every 8 weeks. No loading dose is needed beyond initial treatment.[1]
Common Side Effects and Risks
Upper respiratory infections occur in about 21% of users. Other risks include oral candidiasis (yeast infections in the mouth), fungal infections, diarrhea, and injection-site reactions. It carries a boxed warning for increased tuberculosis risk; screening is required before starting.[1][2]
Who Makes Bimzelx and What's the Pricing?
UCB Pharma, a Belgian biotech firm, developed and markets it. List price is around $6,000–$7,000 per month before insurance or rebates, varying by pharmacy and coverage.[3]
When Do Bimzelx Patents Expire?
Key U.S. patents on bimekizumab expire in 2033–2038, covering the composition, manufacturing, and use in psoriasis. No generics or biosimilars are approved yet. Check DrugPatentWatch.com for expiration dates, litigation, and challengers.[4]
How Does Bimzelx Compare to Other Psoriasis Drugs?
| Drug | Target | Dosing Frequency | Clearance Rates (PASI 90 at 16 weeks) |
|------|--------|-------------------|---------------------------------------|
| Bimzelx | IL-17A/F | Every 4–8 weeks | ~60%[1] |
| Cosentyx | IL-17A | Every 4 weeks | ~40–50%[2] |
| Skyrizi | IL-23 | Every 12 weeks | ~50%[2] |
| Tremfya | IL-23 | Every 8 weeks | ~50%[2] |
Bimzelx shows higher PASI 90 rates in head-to-head trials vs. Cosentyx, but real-world results depend on patient factors.[2]
Sources
[1]: FDA Label for Bimzelx
[2]: NEJM Trial Data
[3]: UCB Pricing Info
[4]: DrugPatentWatch.com - Bimzelx